
WEIGHT: 53 kg
Breast: Large
One HOUR:70$
NIGHT: +40$
Services: Striptease, Facial, Swinging, Mistress, Fisting anal
Official websites use. Share sensitive information only on official, secure websites. The approval of epoetin biosimilars in the European Union requires extensive scientific evaluation and stringent regulatory procedures, including post-marketing studies.
The ORHEO place of biOsimilaRs in the therapeutic management of anaemia secondary to chemotherapy in HaEmatology and Oncology study was an observational, longitudinal, multicentre study performed in France to evaluate the efficacy and safety of biosimilar epoetins for the treatment of chemotherapy-induced anaemia CIA in the clinical setting.
Patient characteristics were recorded at baseline along with anaemia-related information, such as observed and target Hb as chosen by the treating clinician , brand and dose of epoetin biosimilar prescribed, and details of any other treatments. Patients were then followed-up at 3 and 6 months. Other endpoints included adverse events, achievement of target Hb and associated treatments.
Mean baseline Hb was 9. Hb response was achieved in Overall mean change in Hb level was 1. Transfusion and thromboembolic event rates were 9. Epoetin zeta was effective and well tolerated in the management of CIA in patients with solid tumours, lymphoma and myeloma.
Trial registration number: NCT date of registration: 14 May Supportive therapy for patients undergoing chemotherapy can be of great benefit in alleviating undesirable consequences of this specific treatment. One such consequence is chemotherapy-induced anaemia CIA , a common complication of myelosuppressive chemotherapy across a large range of cancer types. Successful Hb response through supportive therapy has been demonstrated to improve fatigue and QoL significantly in patients with CIA [ 2 ].